The prognostic value of myocardial salvage index by cardiac

Abstract

 Objective: To assess the prognostic value of myocardial salvage index (MSI) by cardiac magnetic resonance (CMR) in ST-segment elevation myocardial infarction (STEMI) patients.

Methods: We systematically searched PubMed, Embase, Web of Science, Cochrane Central, China National Knowledge Infrastructure, and Wanfang Data to identify primary studies reporting MSI in STEMI patients with major adverse cardiovascular events (MACE) comprised of death, myocardial reinfarction, and congestive heart failure. The

Results: Eighteen studies were included covering twelve unique cohorts. Eleven cohorts measured MSI using T2-weighted imaging and T1-weighted late gadolinium enhancement, while one cohort applied T2-mapping and T1-mapping. The pooled MSI (95% CI) was 44% (39 to 49%; 11 studies, 2946 patients), and the pooled MACE rate (95% CI)

Conclusions: MSI presents potential in predicting MACE in STEMI patients. The prognostic value of MSI using advanced CMR techniques for adverse cardiovascular events needs

Disclaimer:

Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.

Association between the beta-blockers, calcium channel blockers,

Methods: The present meta-analysis has been performed as per the guidelines of (PRISMA). An inclusive literature search was made without any limitations on language using the electronic databases Cochrane Library, EMBASE, and PubMed up to November 2022. The outcomes evaluated in this meta-analysis involved all-cause mortality

Results: In total, 10 articles were included in the present meta-analysis, with a pooled sample size of 12 940 HFpEF patients. In comparison with placebo, both BB and CCB substantially reduced the risk of all-cause mortality and hospitalization. However, BB are more effective because they provide a significant reduction in all-cause mortality (risk ratio (RR) = 0.60; 95% confidence interval [CI] = 0.43-0.83; p = .002] and hospitalization (RR = 0.54; 95% CI = 0.37-0.80; p =.002) as compared with CCB with a risk ratio of all-cause mortality (RR = 0.77; 95% CI = 0.60-0.98; p = .03) and hospitalization (RR = 0.63; 95% CI = 0.44-0.90; p < .00001). A random-effects model was used because of high heterogeneity between the studies (I2 > 70%).

Conclusions: The current meta-analysis suggests that BBs were more beneficial than CCB in reducing all-cause mortality and hospitalization duration in patients with HFpEF.

Disclaimer:

Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.

Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial

 2023 Jun 2;9(4):328-336. doi:10.1093/ehjcvp/pvad006.

Abstract

Methods and results: In the TWILIGHT (Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention) trial, after 3 months of ticagrelor plus aspirin, high-risk patients were maintained on ticagrelor and randomized to aspirin or placebo for 1 year. Anaemia was defined as haemoglobin <13 g/dL for men and <12 g/dL for women. The primary endpoint was Bleeding Academic Research Consortium (BARC) 2, 3, or 5 bleeding. The key secondary endpoint was a composite of all-cause death, myocardial infarction, or stroke.Out of 6828 patients, 1329 (19.5%) had anaemia and were more likely to have comorbidities, multivessel disease, and to experience bleeding or ischaemic complications than non-anaemic patients. Among anaemic patients, BARC 2, 3, or 5 bleeding occurred less frequently with ticagrelor monotherapy than with ticagrelor plus aspirin [6.4% vs. 10.7%; hazard ratio (HR) 0.60; 95% confidence interval (CI) 0.41-0.88; P =0.009]; the rate of the key secondary endpoint was similar in the two arms (5.2% vs. 4.8%; HR 1.07; 95% CI 0.66-1.74; P = 0.779). These effects were consistent in patients without anaemia (interaction P values 0.671 and 0.835, respectively).

Conclusion: In high-risk patients undergoing PCI, ticagrelor monotherapy after 3 months of ticagrelor-based dual antiplatelet therapy was associated with a reduced risk of clinically relevant bleeding without any increase in ischaemic events

Impact of Diabetes Mellitus on Benefit of β-Blocker Therapy After

  https://doi.org/10.1016/j.amjcard.2023.04.022

Abstract

Background:

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced

https://doi.org/10.1093/ehjcvp/pvad036

 Abstract

Background:

Guideline recommendations for the

Objectives:

We investigated predictors of

Methods:

Patients with HFmrEF (EF 40–49%) from

Results:

Of 12 421 patients with HFmrEF,

Conclusions:

RASI/ARNI and beta-blockers were

Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion

The authors sought to relate spontaneous reperfusion to the

Methods:

In a prospective study, blood from STEMI patients

Results:

Spontaneous reperfusion was associated with a longer

Conclusions:

We demonstrate a novel hematological signature in

Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of

2023 May;38(4):698-705. doi: 10.1177/02676591221076284.

 Abstract

Objective: Ticagrelor may be an alternative to aspirin as it provides

Methods: We searched PubMed, Embase, EBSCO, and Cochrane databases from

Results: Seven trials including 4305 patients (2153 randomized to

Conclusions: Compared with non-ticagrelor therapy, ticagrelor decreased the

Clinical Efficacy and Safety of Early Intravenous

Cardiovasc Drugs Ther. 2023 Apr 1.doi: 10.1007

Background: Several clinical studies have produced diverse results regarding

Methods: A database search was conducted using PubMed, EMBASE, the

Results: Seven RCTs with 1428 patients were included in this study, with

Conclusion: Intravenous beta-blockers improved the MSI, decreased the risk

Safe and Effective Early Use of Betablockers after

Sex-stratified differences in early antithrombotic

Am

Background: The mechanisms underlying the increased risk of bleeding that

Methods: The COMPARE CRUSH trial randomized patients presenting with

Results: Out of 633 STEMI patients, 147 (23%) were female. Females

Conclusions: In this contemporary STEMI cohort, female STEMI patients remain